Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06QBX
|
|||
| Drug Name |
VDA-1102
|
|||
| Indication | Actinic keratosis [ICD-11: EK90.0; ICD-10: L57.0; ICD-9: 702] | Phase 2 | [1] | |
| Company |
Vidac Pharma Jerusalem, Israel
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Hexokinase-2 (HK2) | Target Info | Modulator | [1] |
| Voltage-dependent anion-selective channel 1 (VDAC1) | Target Info | Modulator | [1] | |
| KEGG Pathway | Glycolysis/Gluconeogenesis | |||
| Fructose and mannose metabolism | ||||
| Galactose metabolism | ||||
| Starch and sucrose metabolism | ||||
| Amino sugar and nucleotide sugar metabolism | ||||
| Neomycin, kanamycin and gentamicin biosynthesis | ||||
| Metabolic pathways | ||||
| Carbon metabolism | ||||
| HIF-1 signaling pathway | ||||
| Insulin signaling pathway | ||||
| Type II diabetes mellitus | ||||
| Carbohydrate digestion and absorption | ||||
| Central carbon metabolism in cancer | ||||
| Calcium signaling pathway | ||||
| cGMP-PKG signaling pathway | ||||
| Necroptosis | ||||
| Cellular senescence | ||||
| NOD-like receptor signaling pathway | ||||
| Cholesterol metabolism | ||||
| Parkinson disease | ||||
| Huntington disease | ||||
| Influenza A | ||||
| Human T-cell leukemia virus 1 infection | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.